Subcutaneous amivantamab induces durable responses in metastatic head, neck cancer

Subcutaneous amivantamab induced rapid and durable responses among patients with HPV-unrelated recurrent or metastatic head and neck cancer, according to study results.Nearly half of patients responded to therapy and more than three-quarters experienced shrinkage of target lesions, findings presented at ASCO Annual Meeting and published simultaneously in Journal of Clinical Oncology showed.